FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a vaccine for subtilisin-kexin-9 type proteinase (PCSK9), and can be used in medicine for treating or preventing PCSK9 related diseases selected from hyperlipidemia, hypercholesterolemia, atherosclerosis or neoplastic diseases.
EFFECT: conjugate of a variant of PCSK9 fragment with SEQ ID NO: 1 with an immunogenic protein carrier can be used as a part of a vaccine for enhanced induction of PCSK9 antibody formation compared to a natural PCSK9 fragment conjugate.
7 cl, 6 dwg, 2 tbl, 1 ex
Title | Year | Author | Number |
---|---|---|---|
VACCINE | 2012 |
|
RU2640258C2 |
PCSK9 ANTAGONISTS | 2009 |
|
RU2528735C2 |
PCSK9 ANTAGONISTS | 2014 |
|
RU2618869C2 |
PCSK9 VACCINE | 2010 |
|
RU2538162C2 |
TREATING WITH ANTI-PCSK9 ANTIBODIES | 2012 |
|
RU2576034C2 |
ANTIBODIES WITH PH-DEPENDENT ANTIGEN BINDING | 2011 |
|
RU2570729C2 |
ANTI-PCSK9 ANTIBODY AND ITS APPLICATION | 2016 |
|
RU2756012C2 |
HUMAN ANTIBODIES TO PCSK9 FOR USE IN METHODS OF TREATING PARTICULAR GROUPS OF SUBJECTS | 2012 |
|
RU2603481C2 |
IMMUNOGENIC PEPTIDE FRAGMENT OF ADAMTS-7 METALLOPROTEINASE AND ITS USE IN COUNTERACTING ATHEROSCLEROSIS AND RELATED DISEASES | 2020 |
|
RU2799526C1 |
PHARMACEUTICAL COMPOSITIONS CONTAINING ANTIBODIES TO HUMAN PCSK9 | 2012 |
|
RU2604139C2 |
Authors
Dates
2019-09-02—Published
2015-02-23—Filed